Tyra Biosciences, Inc. (TYRA) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Tyra Biosciences, Inc. (TYRA) posted $0 in revenue for fiscal 2025, with a net loss of $119.95M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Tyra Biosciences, Inc.
Tyra Biosciences, Inc. has grown revenue from $0 to $0 over the last 6 fiscal years.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Tyra Biosciences, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Tyra Biosciences, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-9.34M | $-26.29M | $-55.33M | $-69.13M | $-86.48M | $-119.95M |
| Net margin | — | — | — | — | — | — |
Source: Tyra Biosciences, Inc. SEC filings (10-K).
Tyra Biosciences, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 29.6% over 4 years (41.4M → 53.7M) — existing holders' stakes are being diluted.
Explore 6 years of Tyra Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TYRA in your portfolio →
Tyra Biosciences, Inc. financial history by metric
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Tyra Biosciences, Inc. — frequently asked questions
What is Tyra Biosciences, Inc.'s revenue?
Tyra Biosciences, Inc. (TYRA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Tyra Biosciences, Inc. profitable?
No — TYRA reported a net loss of $-119.95M in fiscal 2025.
What is TYRA's P/E ratio?
Tyra Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Tyra Biosciences, Inc. have?
As of fiscal year 2025, TYRA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Tyra Biosciences, Inc.'s market cap?
Tyra Biosciences, Inc. (TYRA) has a market capitalization of about $1.55B, based on the latest data in our nightly-refreshed cache.
When does Tyra Biosciences, Inc.'s fiscal year end?
TYRA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Tyra Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.